Immunosignaturing: A critical review

Trends in Biotechnology

Volumn 31, Issue 1, 2013, Pages 45-51

  Sykes, Kathryn F ^a   Legutki, Joseph B ^b   Stafford, Phillip ^b  

^a HealthTell Inc   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Antibody profiling; Biomarker discovery; Health monitoring; Immunodiagnostics; Peptide microarray

Indexed keywords

BIO-MARKER DISCOVERY; COMPLEX INTERACTION; CRITICAL REVIEW; HEALTH MONITORING; IMMUNE SYSTEMS; IMMUNODIAGNOSTICS;

BIOTECHNOLOGY;

ANTIBODIES;

CROSS REACTION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PROCEDURES; IMMUNOSIGNATURING; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN MICROARRAY; REVIEW;

ANTIBODIES; BIOLOGICAL MARKERS; BIOMEDICAL TECHNOLOGY; CROSS REACTIONS; EARLY DIAGNOSIS; HUMANS; MICROARRAY ANALYSIS;

EID: 84871680408     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2012.10.012     Document Type: Review

References (66)

1. Schuster S.C. Next-generation sequencing transforms today's biology. Nat. Methods 2008, 5:16-18.
2. Anderson N.L., Anderson N.G. The human plasma proteome. Mol. Cell. Proteomics 2002, 1:845-867.
3. Diamandis E.P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool. Mol. Cell. Proteomics 2004, 3:367-378.
4. Fushiki T., et al. Identification of biomarkers from mess spectrometry data using a "common" peak approach. BMC Bioinform. 2006, 7:358.
5. Sulzer B., et al. Memory in idiotypic networks due to competition between proliferation and differentiation. Bull. Math. Biol. 1993, 55:1133-1182.
6. Cenci S., Sitia R. Managing and exploiting stress in the antibody factory. FEBS Lett. 2007, 581:3652-3657.
7. Cooperman J., et al. Cell division rates of primary human precursor B cells in culture reflect in vivo rates. Stem Cells 2004, 22:1111-1120.
8. Forster I., Rajewsky K. The bulk of the peripheral B-cell pool in mice is stable and not rapidly renewed from the bone marrow. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:4781-4784.
9. Hao Z., Rajewsky K. Homeostasis of peripheral B cells in the absence of B cell influx from the bone marrow. J. Exp. Med. 2001, 194:1151-1164.
10. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1:845-867.
11. Hori S.S., Gambhir S.S. Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci. Transl. Med. 2012, 3:109ra116.
12. Brown P.O., Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009, 6:e1000114.
13. Acierno J.P., et al. Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies. J. Mol. Biol. 2007, 374:130-146.
14. Usami A., et al. The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody. J. Pharm. Biomed. Anal. 1996, 14:1133-1140.
15. Chase B.A., et al. Evaluation of biological sample preparation for immunosignature-based diagnostics. Clin. Vaccine Immunol. 2012, 19:352-358.
16. Harn N., et al. Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability. J. Pharm. Sci. 2007, 96:532-546.
17. James L.C., Tawfik D.S. The specificity of cross-reactivity: promiscuous antibody binding involves specific hydrogen bonds rather than nonspecific hydrophobic stickiness. Protein Sci. 2003, 12:2183-2193.
18. Wang L.F., Yu M. Epitope identification and discovery using phage display libraries: applications in vaccine development and diagnostics. Curr. Drug Targets 2004, 5:1-15.
19. Valentini D., et al. Humoral 'reactome' profiles using peptide microarray chips. Trends Immunol. 2010, 31:399-400.
20. Stafford P., et al. Physical characterization of the 'immunosignaturing effect'. Mol. Cell. Proteomics 2012, 11. M111.011593.
21. Price J.V., et al. On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions. Nat. Med. 2012, 18:1434-1440.
22. Willats W.G.T. Phage display: practicalities and prospects. Plant Mol. Biol. 2002, 50:837-854.
23. Janeway C., Travers J. Immunobiology: The Immune System in Health and Disease 1997, Current Biology Limited.
24. Nobrega A., et al. Functional diversity and clonal frequencies of reactivity in the available antibody repertoire. Eur. J. Immunol. 1998, 28:1204-1215.
25. Restrepo L., et al. Feasibility of an early Alzheimer's disease immunosignature diagnostic test. J. Neuroimmunol. 2011, 10.1016/j.jneuroim.2012.09.014.
26. Restrepo L., et al. Application of immunosignatures to the assessment of Alzheimer's disease. Ann. Neurol. 2011, 70:286-295.
27. Hughes, A. et al. (2012) Immunosignaturing can detect products from molecular markers in brain cancer. PLoS ONE (in press).
28. Brown J., et al. Statistical methods for analyzing immunosignatures. BMC Bioinform. 2011, 12:349.
29. Kukreja M., et al. Immunosignaturing microarrays distinguish antibody profiles of related pancreatic diseases. Proteomics Bioinform. 2012, S6.
30. Legutki J.B., et al. A general method for characterization of humoral immunity induced by a vaccine or infection. Vaccine 2010, 28:4529-4537.
31. Halperin R.F., et al. Exploring antibody recognition of sequence space through random-sequence peptide microarrays. Mol. Cell. Proteomics 2011, 10. M110.000786.
32. Halperin R., et al. GuiTope: an application for mapping random-sequence peptides to protein sequences. BMC Bioinform. 2012, 13:1.
33. Draghici S. Statistics and Data Analysis for Microarrays Using R and Bioconductor 2012, Chapman & Hall/CRC.
34. Yang Y., et al. Segmentation and intensity estimation for microarray images with saturated pixels. BMC Bioinform. 2011, 12:462.
35. Brown J.R., et al. Statistical methods for analyzing immunosignatures. BMC Bioinform. 2011, 12:349.
36. Kukreja M., et al. Comparative study of classification algorithms for immunosignaturing data. BMC Bioinform. 2012, 13:139.
37. Hughes A.K., et al. Immunosignaturing can detect products from molecular markers in brain cancer. PLoS ONE 2012, 7:e40201.
38. Agarwal A., et al. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol. Invest. 2003, 32:17-30.
39. Huang J., et al. MIMOX: a web tool for phage display based epitope mapping. BMC Bioinform. 2006, 7:451.
40. Mackey A.J., et al. Getting more from less: algorithms for rapid protein identification with multiple short peptide sequences. Mol. Cell. Proteomics 2002, 1:139-147.
41. Moreau V., et al. Discontinuous epitope prediction based on mimotope analysis. Bioinformatics 2006, 22:1088-1095.
42. Casey J.L., et al. Phage display of peptides in ligand selection for use in affinity chromatography. Methods Mol. Biol. 2008, 421:111-124.
43. Kroening K., et al. Autoreactive antibodies raised by self derived de novo peptides can identify unrelated antigens on protein microarrays. Are autoantibodies really autoantibodies?. Exp. Mol. Pathol. 2012, 92:304-311.
44. Chen Y.T., et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:6919-6923.
45. Borrebaeck C.A.K. Antibodies in diagnostics - from immunoassays to protein chips. Immunol. Today 2000, 21:379-382.
46. Butler J.E. Solid supports in enzyme-linked immunosorbent assay and other solid-phase immunoassays. Methods 2000, 22:4-23.
47. Butler J.E., et al. The immunochemistry of sandwich ELISAs - VI. Greater than 90% of monoclonal and 75% of polyclonal anti-fluorescyl capture antibodies (CAbs) are denatured by passive adsorption. Mol. Immunol. 1993, 30:1165-1175.
48. Liu B., et al. Towards proteome-wide production of monoclonal antibody by phage display. J. Mol. Biol. 2002, 315:1063-1073.
49. Uhlen M., Hober S. Generation and validation of affinity reagents on a proteome-wide level. J. Mol. Recognit. 2009, 22:57-64.
50. Schweitzer B., et al. Immune response biomarker profiling application on protoarray protein microarrays. The Urinary Proteome 2010, 243-252. Humana Press. A.J. Rai (Ed.).
51. Hanash S. Disease proteomics. Nature 2003, 422:226-232.
52. Reddy M.M., et al. Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell 2011, 144:132-142.
53. Panicker R.C., et al. Recent advances in peptide-based microarray technologies. Comb. Chem. High Throughput Screen. 2004, 7:547-556.
54. Fu J., et al. Exploring peptide space for enzyme modulators. J. Am. Chem. Soc. 2010, 132:6419-6424.
55. Fu J., et al. Peptide-modified surfaces for enzyme immobilization. PLoS ONE 2011, 6:e18692.
56. Diehnelt C.W., et al. Discovery of high-affinity protein binding ligands - backwards. PLoS ONE 2010, 5:e10728.
57. Boltz K.W., et al. Peptide microarrays for carbohydrate recognition. Analyst 2009, 134:650-652.
58. Foong Y.M., et al. Current advances in peptide and small molecule microarray technologies. Curr. Opin. Chem. Biol. 2012, 16:234-242.
59. Morales Betanzos C., et al. Bacterial glycoprofiling by using random sequence peptide microarrays. Chembiochem 2009, 10:877-888.
60. Falsey J.R., et al. Peptide and small molecule microarray for high throughput cell adhesion and functional assays. Bioconjug. Chem. 2001, 12:346-353.
61. Shreffler W.G., et al. IgE and IgG4 epitope mapping by microarray immunoassay reveals the diversity of immune response to the peanut allergen, Ara h 2. J. Allergy Clin. Immunol. 2005, 116:893-899.
62. Cretich M., et al. Epitope mapping of human chromogranin A by peptide microarrays. Peptide Microarrays 2009, 221-232. Humana Press. M. Cretich, M. Chiari (Eds.).
63. Mohan S., et al. Association energetics of cross-reactive and specific antibodies. Biochemistry 2009, 48:1390-1398.
64. Thorpe I.F., Brooks C.L. Molecular evolution of affinity and flexibility in the immune system. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:8821-8826.
65. Zhou Z.H., et al. Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J. Autoimmun. 2007, 29:219-228.
66. Stafford P. Immunosignaturing: challenges and opportunities. Bioinformatics and Proteomics 2010, Department of Genetics, Genomics & Bioinformatics, UCR.